Why the study?
Does the Micra leadless VVI pacemaker reduce reinterventions and chronic complications compared to transvenous VVI pacing in US Medicare patients?
Does the Micra leadless VVI pacemaker reduce reinterventions and chronic complications compared to transvenous VVI pacing in US Medicare patients?
In a real-world Medicare population, leadless VVI pacing significantly reduced reinterventions and chronic complications compared to transvenous pacing at 2 years, without affecting mortality.
Answers are grounded in this paper and cite their sources.
May support leadless VVI preference in Medicare patients; extends observational data but leaves open randomized confirmation.
In a real-world study of US Medicare patients, the Micra leadless VVI pacemaker was associated with a 38% lower adjusted rate of reinterventions and a 31% lower adjusted rate of chronic complications compared with transvenous VVI pacing. There was no difference in adjusted all-cause mortality at 2 years.
No takes yet. Share an insight, caveat, or question.
El‐Chami et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: